Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease

Circulation

Volumn 98, Issue 21, 1998, Pages 2235-2240

  Wenzel, René R ^a   Fleisch, Martin ^a   Shaw, Sidney ^b   Noll, Georg ^a,c   Kaufmann, Urs ^a   Schmitt, Rita ^d   Jones, C Richard ^d   Clozel, Martine ^d   Meier, Bernhard ^a   Lüscher, Thomas F ^c  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Angiography; Blood flow; Bosentan; Coronary disease; Endothelin

Indexed keywords

BOSENTAN; CATECHOLAMINE; ENDOTHELIN; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; GLYCERYL TRINITRATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD FLOW VELOCITY; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HEART RATE; HEMODYNAMICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL;

EID: 17344373615     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.21.2235     Document Type: Article

References (12)

1. Lüscher TF, Vanhoutte PM. The Endothelium: Modulator of Cardiovascular Function. Boca Raton, Fla: CRC Press; 1990.
2. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y. Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
3. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990;348:730-732.
4. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990;348:732-735.
5. B receptors mediate contraction to endothelin-1 in human blood vessels. Circulation. 1994;89:1203-1208.
6. Dohi Y, Lüscher TF. Endothelin in hypertensive resistance arteries: intraluminal and extraluminal dysfunction. Hypertension. 1991;18:543-549.
7. Kiowski W, Lüscher TF, Linder L, Bühler FR. Endothelin-1-induced vasoconstriction in humans: reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation. 1991;83:469-475.
8. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JJ. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med. 1991;325:997-1001.
9. Stein PD, Floyd DM, Bisaha S, Dickey J, Girotra RN, Gougoutas JZ, Kozlowski M, Lee VG, Liu EC, Malley MF. Discovery and structureactivity relationships of sulfonamide ETA-selective antagonists. J Med Chem. 1995;38:1344-1354.
10. Stewart DJ, Cernacek P, Costello KB, Rouleau JL. Elevated endothelin-l in heart failure and loss of normal response to postural change. Circulation. 1992;85:510-517.
11. Omland T, Terje Lie R, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation. 1994;89:1573-1579.
12. Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis. 1989;78:225-228.